A randomized Bayesian optimal phase II design with binary endpoint. Issue 2 (4th March 2023)

• Record Type: Journal Article
• Authors: Ding, Yang
• Is Part Of: Journal of biopharmaceutical statistics. Volume 33:Issue 2(2023)
• Page Start: 151
• Page End: 166
• Publication Date: 2023-03-04
• Subjects: Randomized trial -- Bayesian design -- phase II trial -- futility stopping; Pharmacy -- Statistical methods -- Periodicals; Drugs -- Testing -- Statistical methods -- Periodicals; Biometry -- Periodicals; Biopharmaceutics -- Periodicals; Pharmacokinetics -- Periodicals; 615.19
• DOI: 10.1080/10543406.2022.2094938
• Languages: English
• ISSNs: 1054-3406

Abstract

ABSTRACT: In this paper, we propose a randomized Bayesian optimal phase II (RBOP2) design with a binary endpoint (e.g., response rate). A beta-binomial distribution is used to model the binary endpoint for a two-arm phase II trial. Posterior probabilities of the endpoint of interest are evaluated at each interim look and used in the decision to stop the trial due to futility. Compared with other Bayesian designs, the proposed RBOP2 design has the following merits: (i) strongly controls the type I error rate at a pre-defined level; (ii) optimizes the stopping boundaries, thus maximizing the power to detect treatment effects and minimizing the expected sample size for futile treatment; (iii) does not limit the number of interim looks, thus enabling frequent trial monitoring; and (iv) allows the stopping boundaries to be pre-defined in the protocol and is easy to implement. We conduct simulation studies to compare the proposed design with a group sequential design and other Bayesian randomized designs and evaluate its operating characteristics under different scenarios.